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Abstract
In vivo biofilms cause recalcitrant infections with extensive and unpredictable antibiotic tolerance. Here, we demonstrate 
increased tolerance of colistin by Pseudomonas aeruginosa when grown in medium that mimics cystic fibrosis (CF) sputum 
versus standard medium in in vitro biofilm assays, and drastically increased tolerance when grown in an ex vivo CF model 
versus the in vitro assay. We used colistin conjugated to the fluorescent dye BODIPY to assess the penetration of the antibiotic 
into ex vivo biofilms and showed that poor penetration partly explains the high doses of drug necessary to kill bacteria in these 
biofilms. The ability of antibiotics to penetrate the biofilm matrix is key to their clinical success, but hard to measure. Our results 
demonstrate both the importance of reduced entry into the matrix in in vivo- like biofilm, and the tractability of using a fluores-
cent tag and benchtop fluorimeter to assess antibiotic entry into biofilms. This method could be a relatively quick, cheap and 
useful addition to diagnostic and drug development pipelines, allowing the assessment of drug entry into biofilms, in in vivo- like 
conditions, prior to more detailed tests of biofilm killing.
DATA SUMMARY
The authors confirm that all supporting data, code and 
protocols have been provided within the article or through 
the supplementary data file (Document S1).
INTRODUCTION
Biofilm infections of host tissues or indwelling medical devices 
impose a significant health and economic burden, due to the 
high tolerance of biofilm bacteria to host immune attack and 
to antibiotics. Biofilm antibiotic tolerance is a function of 
environmentally cued changes in bacterial physiology and 
gene expression, and reduced penetration of some antibiotic 
molecules through the biofilm matrix [1]. In the case of cystic 
fibrosis (CF) lung disease, plugging of small airways by aggre-
gates of biofilm embedded in abnormal host mucus leads to 
reduced airflow and bronchiectasis [2, 3]. In a recent analysis, 
bacterial lung infection was the strongest predictor of medi-
cation costs in CF, adding on average €3.6K per patient per 
year to direct healthcare costs [4, 5]. Intravenous antibiotic 
treatments, usually administered during acute exacerbations 
of respiratory symptoms, impose a particularly heavy burden: 
in the UK, people with CF spend a median of 27 days/year 
receiving IV antibiotics, often as hospital in- patients [6]. 
There is a narrow choice of antibiotics suitable for admin-
istration in CF, and a poor concordance between antibiotic 
susceptibility testing in diagnostic laboratories and patient 
outcome – even when standard in vitro biofilm platforms are 
employed for testing [7, 8].
Generic in vitro biofilm models (e.g. Calgary device [9, 10], 
flow cells) and standard laboratory growth media are usually 
used to test the efficacy of antibacterial agents, both in a 
diagnostic setting and in research and development pipe-
lines for new agents. It is increasingly recognized that the 
key to optimizing biofilm management is a more context- 
specific approach to mimicking the in- host conditions in the 
infection(s) of interest. The effect of physicochemical envi-
ronment, and especially of host mimicking versus standard 
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known [11–14]. Further, environmental differences between 
specific biofilm contexts are likely to produce different biofilm 
architectures; overall biofilm thickness and 3D structure, as 
well as the production of matrix polymers with different size, 
charge or hydrophobicity, will impact on how easily different 
antibiotics can penetrate the matrix to reach cells [15]. The 
benefits and shortcomings of different in vitro and in vivo 
biofilm models, and limitations on how well standard models 
such as the Calgary device represent in vivo biofilms, have 
been reviewed in detail by other authors [16–18].
We hypothesized that poor penetration of the in vivo matrix 
partly explains the high doses of antibiotic necessary to kill 
Pseudomonas aeruginosa in CF lung biofilms. We focused on 
the antibiotic colistin for two reasons. First, colistin is widely 
prescribed for P. aeruginosa infection in CF and is commonly 
administered by inhalation; this means that topical laboratory 
exposure of biofilms to colistin, by spiking the surrounding 
culture medium, likely mimics in vivo exposure better than 
in the case of antibiotics that are only administered orally or 
through IV. Second, fluorescently labelled colistin was already 
available in one of our laboratories, opening up the possibility 
to assay colistin concentration in biofilm via fluorimetry [19]. 
Finally, colistin is able to bind the P. aeruginosa exopolymer 
Psl [20] and extracellular lipopolysaccharide [21] and may 
adsorb to outer- membrane vesicles [22] – all of which may 
be present in P. aeruginosa biofilms, depending on strain and 
culture conditions.
We first compared the tolerance of the laboratory strain PA14 
and eight CF isolates of P. aeruginosa to colistin in standard 
antibiotic susceptibility testing medium (cation- adjusted 
Müller–Hinton broth, caMHB) and synthetic CF sputum 
medium (SCFM [23]) using planktonic microdilution and 
biofilm eradication assays in a Calgary device. Use of SCFM 
led to increased minimum inhibitory concentration (MIC) in 
microdilution experiments for all strains, and to an increased 
minimum biofilm eradication concentration (MBEC) for 
eight of the nine strains (one showed no change). We then 
grew PA14 and four of the CF isolates in an ex vivo model 
of CF biofilm that combines SCFM and pig bronchiolar 
tissue [24, 25]. Biofilms grown in this model showed drasti-
cally increased colistin tolerance as compared with biofilms 
grown in the Calgary device. To test the hypothesis that this 
increase in tolerance is at least in part due to low penetration 
of the biofilm matrix by colistin, we exposed ex vivo porcine 
lung model (EVPL)- grown biofilms to fluorescently labelled 
colistin to measure the percentage of a dose that was able to 
enter the biofilm. The amount of labelled colistin present in 
biofilms ranged from 12–19 % of the total amount recovered 
from biofilms plus surrounding SCFM, demonstrating poor 
penetration of colistin into the biofilm matrix.
Our results confirm that the in vivo biofilm can prevent 
free diffusion of colistin to bacterial cells, and underline the 
limitations of using simple in vitro biofilm models in which 
bacteria are attached to an inorganic substrate and/or grown 
in medium that does not recapitulate the chemistry of the 
in vivo environment. The EVPL+SCFM model represents an 
improved balance between accurate modelling of the CF lung 
environment and tractability in the laboratory. We propose 
that it could be used to aid antibiotic susceptibility testing 
in diagnostic and drug development contexts. Furthermore, 
EVPL could be combined with fluorescent labelling of in- use 
or novel antibiofilm agents to produce a cheap and simple 
method for assessing how well these molecules enter the 
biofilm matrix. This could be valuable in the search for new 
and improved antibiofilm agents.
METHODS
Bacterial strains
The laboratory strains PAO1 (Nottingham isolate) PA14 
(a gift from Leo Eberl) and eight isolates of P. aeruginosa 
from a chronically colonized person with CF (SED6, SED7, 
SED8, SED9, SED11, SED13, SED17, SED19 [26]) were used 
in this work. The CF strains had previously been shown 
to vary considerably in antibiotic resistance profile, and in 
biofilm- forming ability as measured by crystal violet staining 
following growth in lysogeny broth (LB) in a Calgary biofilm 
device (S. Darch, personal communication) Colonies of 
frozen stocks were obtained by growth on LB agar at 37 °C 
for 18–24 h (PAO1, PA14) or 48 h (CF isolates).
Synthetic cystic fibrosis sputum medium (SCFM)
SCFM was made following the recipe of Palmer et al. [23], 
with the modification that glucose was removed because 
previous work suggested that this promoted the growth of 
endogenous bacteria present on pig lung tissue. Even when 
glucose is present in SCFM, P. aeruginosa preferentially uses 
amino acids and short- chain fatty acids as carbon sources, 
and a recent transcriptomic study shows that this is a good 
reflection of P. aeruginosa metabolism in CF in vivo [23, 27].
MIC and MBEC testing
The MIC and minimum biofilm eradication concentration 
(MBEC) of colistin (Acros organics) for the strains were 
assayed by Warwick’s Antimicrobial Screening Facility 
following Clinical and Laboratory Standards Institute (CLSI 
guidelines) in cation- adjusted Müller–Hinton broth and 
in SCFM. MIC testing was performed according to CLSI 
guidelines M7- A9 (Methods for Bacteria that Grow Aero-
bically), M24- A (Testing of Mycobacteria, Nocardiae, and 
Other Aerobic Actinomycetes) and M100- S24 (Performance 
Standards for Antimicrobial Susceptibility Testing). MBEC 
testing used the Calgary biofilm device (peg lid assay) and 
the methods published by Moskowitz et al. [10].
EVPL
The EVPL was prepared as described previously [24, 25], 
except that SCFM was not supplemented with antibiotics to 
repress the growth of any endogenous bacteria present on the 
lung tissue: this was to prevent any interference with assess-
ment of colistin efficacy in later experiments. P. aeruginosa 
has been shown to produce CF- like biofilm in this model [24].
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Pig lungs were obtained from Quigley and Sons, Cubbington, 
and John Taylor and Son, Earlsdon, and dissected on the 
day of delivery under sterile conditions. The pleura of the 
ventral surface was heat- sterilized using a hot pallet knife. A 
sterile razor blade was then used to make an incision in the 
lung, exposing the bronchiole. A section of the bronchiole 
was extracted and the exterior alveolar tissue removed using 
dissection scissors. Bronchiolar sections were washed in a 
1 : 1 mix of Dulbecco’s modified Eagle’s medium (DMEM) 
and RPMI 1640 supplemented with 50 µg ml−1 ampicillin 
(Sigma- Aldrich). Bronchioles were then cut into squares, 
with a further two washes in DMEM+RPMI+ampicillin 
during dissection. The bronchiole squares were then washed 
twice in SCFM (no antibiotics), UV- sterilized for 5 min in a 
germicidal cabinet and transferred to individual wells of a 
24- well plate containing 400 µl SCFM solidified with 0.8 % 
(w/v) agarose per well. Tissue sections were inoculated by 
touching a sterile 29G hypodermic needle (Becton Dickinson 
Medical) to the surface of a P. aeruginosa colony on LB agar, 
and gently piercing the surface of the tissue section. Unin-
fected control sections were mock inoculated with a sterile 
needle. Five hundred microlitres of SCFM was added to each 
well. Plates were sealed with Breathe- Easier gas- permeable 
membrane (Diversified Biotech) and incubated at 37 °C for 
the desired length of time.
Assessing repeatability of P. aeruginosa biofilm 
load on ex vivo pig bronchiole
Eighteen bronchiolar sections from each of three sets of 
pig lungs were prepared as above. Twenty- four- well plates 
containing tissues were photographed using a 20 MP digital 
camera placed at a set height on a copy stand and these images 
were later used to calculate the surface area of each tissue 
section using the freehand select tool in ImageJ: as we dissect 
tissues by hand we wanted to determine whether variation in 
section size affected bacterial load. The mean size of tissue 
section was 44 mm2 (sd 11.5 mm2). Six sections of tissue were 
inoculated with PA14 and six with PAO1; the remaining 
six were left uninoculated. After 2 and 7 days incubation 
at 37 °C, half of the tissue sections plus associated biofilm 
were removed, briefly washed in 500 µl PBS in a fresh 24- well 
plate to remove loosely adhering planktonic cells, and then 
placed into 1 ml PBS in screw- cap homogenization tubes 
(Fisherbrand) containing 18 2.38 mm metal beads (Fisher-
brand). Tissue was bead- beaten in a FastPrep-24 5G (MP 
Biomedicals) for 40 s at 4 m s−1 to recover the bacteria from 
the tissue- associated biofilm. Bacterial load was calculated 
by serially diluting the homogenates, plating on LB agar and 
counting colony- forming units (c.f.u.).
Production of labelled colistin
This process is described in detail by Sabnis et al. [19]. Briefly, 
colistin was labelled by incubation with BODIPY FL SE 
D2184 (Thermo Fisher Scientific) and sodium bicarbonate 
for 2 h at 37 °C; unbound BODIPY was removed by dialysis; 
and successful labelling was confirmed by time- of- flight mass 
spectrometry.
The effect of colistin on EVPL-grown biofilms
PA14 and clinical isolates SED6, SED8, SED17 and SED19 
were cultured in EVPL+SCFM for 2 days, and tissue pieces 
plus surrounding biofilm were then transferred to new 
24- well plates containing 1 ml fresh SCFM+colistin at 0.5× 
in vitro MIC in SCFM, 4× in vitro MIC in SCFM, 0.5× Calgary 
device MBEC in SCFM, 4× Calgary device MBEC in SCFM 
and 10× Calgary device MBEC in SCFM, or antibiotic- free 
SCFM (three pieces of tissue per strain, per treatment). The 
tissue sections with associated biofilms were incubated in 
these treatment plates for 18 h at 37 °C, and then bacteria were 
recovered, bead- beaten as above and diluted and plated on LB 
agar for enumeration of viable c.f.u.
Treatment of EVPL biofilms with BODIPY/colistin
The addition of the BODIPY- tag has been shown to reduce 
bactericidal activity in planktonic culture (MIC in microdilu-
tion assay in MHB increased from 0.5 µg ml−1 to 1 µg ml−1 
[19]). Thus, concentrations of BODIPY/colistin that corre-
spond to sub- inhibitory and bactericidal concentrations of 
unlabelled colistin were chosen from inspection of the data 
on EVPL biofilms treated with unlabelled colistin. Following 
CLSI recommendations (M26- A, Methods for Determining 
Bactericidal Activity of Antimicrobial Agents) the minimum 
bactericidal concentration (MBC) of colistin in the EVPL 
was defined as the lowest concentration causing a ≥3- log10 
reduction in median c.f.u. recovered from biofilms, compared 
with untreated biofilms. These concentrations were chosen 
as ‘bactericidal’ concentrations of BODIPY/colistin to use in 
fluorescent colistin penetration assays. We chose 2 µg ml−1 as 
the sub- inhibitory concentration for later work with PA14, 
and 8 µg ml−1 as the sub- inhibitory concentration for later 
work with all CF isolates.
PA14, SED6, SED8, SED17 and SED19 were inoculated into 
replica pieces of EVPL and incubated for 2 days at 37 °C to 
form mature biofilm, and tissue pieces were then transferred 
individually to 30 ml soda glass screw- top vials containing 
1 ml fresh SCFM alone or 1 ml SCFM+colistin labelled with 
BODIPY FL SE D2184 (succinimidyl ester; Thermo Fisher 
Scientific) at concentrations corresponding to sub- inhibitory 
or bactericidal concentrations of unlabelled colistin. Three 
uninfected pieces of EVPL were incubated alongside the 
infected tissue sections and transferred individually to 30 ml 
soda glass screw- top vials containing 1 ml fresh SCFM alone. 
Labelled colistin was produced as described previously [19]. 
Tubes were incubated for 18 h at 37 °C. Glass vials were used 
for these experiments because colistin can bind plastic and 
we wished to minimize loss to binding of the culture vessel 
in order to measure the proportion of colistin entering the 
biofilms as accurately as possible. A pilot experiment in which 
BODIPY/colistin exposure was conducted in plastic 24- well 
plates (Corning Costar) resulted in only ~50 % of the original 
BODIPY/colistin dose being recovered at the end of the treat-
ment period, consistent with colistin binding plastic (data 
not shown).
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Tissue with associated biofilm was removed from the glass 
tubes and homogenized in 1 ml SCFM. Replica aliquots of this 
homogenate were used for c.f.u. plating. BODIPY/colistin was 
immediately quantified in 100 µl aliquots of tissue+biofilm 
homogenate and surrounding SCFM by fluorimetry (100 µl 
in a black 96- well plate with ex/em 485/535 nm in a Tecan 
SPARK 10M multimode plate reader). There was slightly 
more background fluorescence signal from infected but 
untreated EVPL sections than from uninfected untreated 
EVPL (see Document S1, available in the online version of this 
article), therefore fluorescence values from samples exposed 
to BODIPY/colistin were standardized by subtracting the 
mean fluorescence measured in homogenate/surrounding 
ASM from tissues infected by the same strain but exposed to 
SCFM with no BODIPY/colistin. A calibration curve using 
BODIPY/colistin in SCFM (Fig. S5) was used to calculate 
total amounts of BODIPY/colistin in the whole biofilm and 
the whole volume of surrounding SCFM. The percentage of 
the original dose of BODIPY/colistin recovered from both 
biofilm and SCFM combined was then calculated, to deter-
mine if any of the dose had been lost due to binding the glass, 
lung tissue and/or homogenization beads.
RESULTS
Effect of SCFM on MIC and MBEC of colistin
As expected, the inhibitory concentration of colistin varied 
depending on culture medium (SCFM usually >caMHB) and 
growth mode (MBEC >MIC in all cases but one) (Fig. 1). For 
7 of the 10 isolates, conducting MIC testing in SCFM instead 
of caMHB led to a change in classification from sensitive to 
resistant. We selected CF isolates SED6, SED8, SED17 and 
SED19 for further work with the EVPL, as these had a range 
of MIC/MBEC values (MIC 1–4 µg ml−1 in caMHB and 32–64 
µg ml−1 in SCFM; MBEC 32–128 µg ml−1 in both media) and 
included two isolates for which MBEC=MIC in SCFM (SED6, 
SED8) and two for which MBEC >MIC in SCFM (SED17, 
SED19).
Reproducibility of biofilm load associated with 
tissue in EVPL
Reproducibility of biofilm load is essential in any model 
system that is intended for use in the testing of antibiofilm 
or antibacterial agents. We therefore assessed the reproduc-
ibility of biofilm load between pieces of tissue from the same/
different lungs by measuring the c.f.u. (by plating on LB agar) 
in biofilms of PAO1 and PA14 at 2 and 7 days post- infection 
(p.i.). We wished first to address two questions. First, whether 
there was a statistically significant interaction between lung 
and P. aeruginosa strain in determining total c.f.u. or c.f.u. 
mm−2, i.e. did any difference between PA14 and PAO1 depend 
on whether they were in tissue from lungs 1, 2 or 3? A lack of 
such an interaction would suggest that experimental results 
are robust to any natural variation in tissue between lungs 
taken from different animals. Second, we wished to calculate 
the statistical repeatability of total c.f.u. or c.f.u. mm−2 across 
lungs 1–3 for each of the two strains as a measure of reproduc-
ibility. Based on the answers to these two questions, we then 
aimed to make decision about (1) whether future experiments 
should measure the effects of antibiotics in terms of total c.f.u. 
or whether we should standardize for variation in the size 
of hand- cut tissue sections by working with counts of c.f.u. 
mm−2; and (2) whether one of the two laboratory strains grew 
more consistently in the model and thus would be better to 
use as a standard ‘wild- type’ in future work.
Fig. S1 shows photographs of tissues at inoculation and at 2 
and 7 days p.i.; P. aeruginosa growth is clearly visible due to 
the typical blue- green pigmentation of this species. All colo-
nies recovered from tissue infected with P. aeruginosa were 
identified as P. aeruginosa by morphology; uninfected tissues 
Fig. 1. MIC by broth microdilution and MBEC in Calgary biofilm device 
of colistin for PA14, PAO1 and eight CF isolates of P. aeruginosa. Open 
symbols show values for tests conducted in cation- adjusted Müller–
Hinton broth, closed symbols show values for tests conducted in 
synthetic CF sputum medium; note that for SED 8, the MBEC was the 
same in both media. The dashed lines denote the CLSI breakpoints for 
classification as sensitive (≤2 µg ml−1) or resistant (≥4 µg ml−1) in MIC 
testing in cation- adjusted Müller–Hinton broth. Full data are supplied in 
Document S1; MIC values are taken from two replica assays and MBECs 
are from a single assay.
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cultured a high load of endogenous bacteria from the lungs, 
but these were clearly distinguishable from P. aeruginosa by 
size, shape and colour (P. aeruginosa colonies had a charac-
teristic blue- green colour with a slightly fuzzy margin on LB 
agar, even after growth in the EVPL, whereas endogenous 
bacteria cultured from the uninfected lungs were all white or 
pale yellow with a lenticular appearance). As shown in Fig. S2, 
both PAO1 and PA14 reached biofilm loads comparable with 
those reported for CF (sputum microbiology studies routinely 
give upper limits on the detected P. aeruginosa load of 107–1010 
c.f.u. ml−1 [28–30] and P. aeruginosa aggregates, suggestive 
of detached biofilm fragments, are observable in CF sputum 
[2, 31, 32]). As detailed in Fig. S3 and Table S1, PA14 showed 
more reproducible biofilm loads than PAO1; biofilm loads 
were more repeatable at day 2 than day 7. Standardizing c.f.u. 
by tissue area (measured in mm2 using ImageJ, [33]) did not 
improve repeatability, given the variation inherent in cutting 
tissue by hand (see Document S1), this result was initially 
surprising. However, the tissue may simply be a scaffold, 
or cue, for physiologically realistic biofilm formation and 
maturation, rather than a nutrient source. If bacteria gain 
most of their nutrients from the ASM rather than the tissue, 
attempting to standardize by tissue area is unnecessary – the 
bacteria have reached their carrying capacity, so dividing 
this by area, which varies considerably, adds stochastic vari-
ation. Based on these preliminary results, we decided to use 
PA14 as an example laboratory isolate in further work; to 
grow biofilms for 2 days prior to colistin treatment; and not 
to standardize c.f.u. counts by tissue area when measuring 
viable cells in biofilms.
Biofilms of P. aeruginosa grown in EVPL have 
drastically increased tolerance to colistin
We then aimed to assess the bactericidal activity of colistin 
to EVPL- grown P. aeruginosa, and to identify concentrations 
that were sub- inhibitory or bactericidal to these biofilms 
for use in later experiments with labelled colistin. PA14 and 
clinical isolates SED6, SED8, SED17 and SED19 were cultured 
in EVPL+SCFM for 2 days and the bronchiolar section, plus 
associated biofilm, was transferred to fresh SCFM containing 
colistin at 0.5× in vitro MIC in SCFM, 4× in vitro MIC in 
SCFM, 0.5× Calgary device MBEC in SCFM, 4× Calgary 
device MBEC in SCFM or 10× Calgary device MBEC in 
SCFM, or antibiotic- free SCFM (three pieces of tissue per 
strain, per treatment). The tissue sections and associated 
biofilm were incubated in the colistin treatment for 18 h at 
37 °C, and bacteria were recovered for the enumeration of 
viable c.f.u. The results in Fig. 2 show that growth as biofilms 
in EVPL leads to a drastic increase in colistin tolerance 
compared with growth in in vitro surface- attached biofilm 
models, even when SCFM was used in conjunction with the 
in vitro MBEC platform. This is potentially due to decreased 
bacterial sensitivity, low penetration of colistin into the 
biofilm matrix and/or colistin- binding proteins in the bron-
chiolar tissue [34]
Following CLSI recommendations (M26- A, Methods for 
Determining Bactericidal Activity of Antimicrobial Agents) 
the MBC of colistin in the EVPL was defined as the lowest 
concentration causing a ≥3- log10 reduction in median c.f.u. 
recovered from biofilms, compared with untreated biofilms 
(red circles in Fig. 2). These concentrations were chosen as 
‘bactericidal’ concentrations of BODIPY/colistin to use in 
fluorescent colistin penetration assays (note that addition 
of BODIPY to colistin reduces its activity as an antibiotic). 
This corresponded to 10× the ASM MBEC for PA14 and 
SED8, 4× the ASM MBEC for SED6 and SED17, and 2× the 
SCFM MBEC for SED19. MBCs differed fivefold between the 
strains used. This is likely due to differences in biofilm matrix 
structure or other genetic differences between the isolates, 
as all grew to similar cell densities in the absence of colistin 
[analysis of variance (ANOVA) for effect of strain identity 
on P. aeruginosa c.f.u. in untreated biofilms only: F4,10=1.49, 
P=0.277]. We chose 2 µg ml−1 as the sub- inhibitory concen-
tration for later work with PA14, and 8 µg ml−1 as the sub- 
inhibitory concentration for later work with all CF isolates.
BODIPY-tagged colistin is poorly able to enter 
EVPL-grown biofilms
PA14, SED6, SED8, SED17 and SED19 were inoculated 
into replica pieces of EVPL, incubated for 2 days at 37 °C to 
form mature biofilm, and tissue sections+associated biofilm 
were then transferred individually to the wells of 24- well 
culture plates containing 1 ml fresh SCFM alone or 1 ml 
SCFM containing BODIPY- tagged colistin at concentra-
tions corresponding to sub- inhibitory (2 µg ml−1 for PA14, 
8 µg ml−1 for the CF isolates) or bactericidal concentrations 
(see Fig. 2) of unlabelled colistin. Three uninfected pieces of 
EVPL were incubated alongside the infected tissue sections, 
and transferred individually to 1 ml fresh SCFM with no 
colistin. The tissue and associated biofilm was incubated 
in the BODIPY/colistin treatment for 18 h at 37 °C. A pilot 
experiment using PA14, SED6 and SED8 had confirmed 
that, as in planktonic culture [19], the BODIPY tag signifi-
cantly reduced the antibacterial activity of colistin in this 
biofilm assay (Fig. S3).
At the end of the 18 h exposure to BODIPY/colistin, the 
tissue sections were removed from the treatment and 
biofilms were recovered by bead- beating the individual 
tissue sections in 1 ml SCFM. Replica aliquots of the 
biofilm homogenate were used for c.f.u. plating and for 
quantification of BODIPY/colistin. Aliquots of the SCFM 
surrounding tissue sections in the treatment plate were also 
removed for quantification of BODIPY/colistin. BODIPY/
colistin quantification was performed by fluorimetry in 
a Tecan SPARK 10M multimode plate reader. A calibra-
tion curve of BODIPY/colistin added to SCFM and left 
at 37 °C for 18 h (Fig. S4) was used to calculate the total 
amount of BODIPY/colistin in each biofilm and in the 
SCFM surrounding it. The percentage of the original dose 
of BODIPY/colistin recovered from both biofilm and SCFM 
combined was then calculated to determine if any of the 
dose had been lost due to binding the glass, lung tissue and/
or homogenization beads.
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Fig. 2. Effect of treating 2- day EVPL biofilms of P. aeruginosa with colistin for 18 h. Each data point represents a single tissue section, 
and all tissue sections were taken from the same pair of pig lungs. Horizontal lines denote medians. Red points show the lowest 
concentration of colistin causing a ≥3- log
10
 reduction in c.f.u. compared with untreated biofilms (an outlier for PA14 at 64 µg ml−1 was 
discounted). PA14, SED17 and SED19 had differing values for broth microdilution MIC and Calgary device MBEC tests in SCFM, and so 
were treated with colistin at 0.5× in vitro MIC, 4× in vitro MIC, 0.5× Calgary device MBEC, 4× Calgary device MBEC and 10× Calgary device 
MBEC. SED6 and SED8 had equal broth microdilution MIC and Calgary device MBEC values in SCFM and so were treated with colistin 
at 0.5× in vitro MIC/Calgary device MBEC, 4× in vitro MIC/Calgary device MBEC and 10× in vitro MIC/Calgary device MBEC. Grey dashed 
lines show each isolate’s MBEC in SCFM in the Calgary device. Note that tissues+biofilms were exposed to BODIPY/colistin in a total 
volume of 1 ml SCFM, therefore concentrations correspond to total µg present. Raw data, R code and results of ANOVA analyses of c.f.u. 
in untreated biofilms formed by each strain are supplied in Document S1.
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The recovery rates of total BODIPY/colistin from the 
biofilm homogenate plus surrounding SCFM were fairly 
good for medium–high concentrations, peaking at 
93–100 % recovery from lung sections receiving a dose of 
128 µg ml−1 (Fig. S5). At lower concentrations, recovery 
rates dropped, and became very variable at the lowest dose 
of 2 µg ml−1 (used for PA14). This means that the values 
for this specific treatment may be unreliable. Our recovery 
rate of 70–80 % at the second lowest dose (8 µg ml−1) was 
consistent with recovery rates in soda glass reported by 
a previous study, which compared the loss of colistin to 
substrate binding in various materials [35]. Better rates 
were achieved for higher concentrations, although recovery 
did then start to tail off as concentrations became very high.
Fig. 3a shows the amount of BODIPY/colistin measured 
in the tissue- associated biofilms for the CF isolates; PA14 
is not shown due to the BODIPY quantification becoming 
unreliable in the 2 µg ml−1 treatment (data are supplied in 
Dcument S1). The amount of BODIPY/colistin in biofilms 
ranged from 12–19 % of the total amount recovered from 
biofilms+surrounding SCFM (means and standard devia-
tions: SED6 13±1 %, SED8 16±4 %, SED17 15±2 %, SED19 
13±0 %). To calculate the concentration of BODIPY/
colistin present in biofilms, the volume of the biofilm was 
estimated. Conservative estimation of this concentration is 
achieved by estimating the largest possible biofilm present 
on the tissue. Assuming complete coverage of both sides 
of a 44 mm2 tissue section (the average area, see above) 
by biofilm 100 µm deep (as measured for PA14 in another 
study using this model, [24]), this suggests that a sensible 
maximum biofilm volume to use is 8.8 µl. Fig. 3b shows the 
predicted BODIPY/colistin concentrations in the biofilms 
assuming this volume. The concentrations of BODIPY/
colistin inside the biofilm following supplementation of the 
surrounding SCFM at MBC are between 10 and 100× the 
MBEC measured for the same strain in a Calgary biofilm 
device using SCFM as the culture medium. Obtaining more 
exact measurements of the in- biofilm concentration would 
require imaging work to reveal the exact size and shape 
of biofilms on the tissue surface (for example, two strains 
could form biofilms with the same c.f.u. of bacteria, but 
different amounts of matrix; or one strain may form a much 
thinner biofilm that is spread over a larger area than the 
other).
DISCUSSION
In- host environments can cue changes in bacterial transcrip-
tome and physiology that will affect sensitivity to antibiotics 
(e.g. changes in membrane biology, expression of efflux 
pumps or beta- lactamases [11, 14, 27]). Further, the biofilm 
mode of growth can itself trigger physiological changes in 
antibiotic tolerance (e.g. antibiotics that target transcription/
translation are not active against quiescent cells deep within 
biofilms [36]). But a big issue with in vivo biofilms is the 
inability of antibiotics to penetrate the extracellular matrix. 
Penetration capabilities will depend on the molecular proper-
ties of specific drugs, and on the nature of the in vivo biofilm 
matrix. Understanding how the in vivo matrix retards drug 
penetration is a key question in antibiotic choice, dosing and 
development.
This study shows that colistin, a drug commonly prescribed 
for P. aeruginosa lung infection in people with CF, shows very 
low ability to enter the biofilm matrix when this bacterium 
is grown as a CF- like bronchiolar biofilm. Combining SCFM 
with lung tissue to grow CF- like biofilms leads to tolerance 
of much higher concentrations of colistin than using SCFM 
with a standard in vitro biofilm platform, and this is likely 
a combination of changes in cellular physiology and the 
biofilm matrix architecture, as <20 % of the labelled colistin 
to which biofilms were exposed was able to enter the biofilm 
Fig. 3. Amount of BODIPY/colistin present in biofilms of CF isolates 
after 18 h exposure, as measured by fluorimetry of biofilm homogenate. 
Each symbol is one tissue section, numbers on the x- axis are the sub- 
inhibitory and MBC exposure doses used. (a) BODIPY/colistin measured 
(µg). (b) Concentration of BODIPY/colistin in biofilm, assuming a biofilm 
volume of 8.8 µl. For reference, the lines show 1, 10 and 100× each 
strain’s MBEC as measured in the Calgary biofilm device using SCFM. 
Raw data, and data for PA14, are supplied in Document S1.
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(these percentages take into account loss of colistin due to 
adsorption or binding to the lung tissue, glass exposure vial, 
plastic homogenization tube and/or metal homogenization 
beads). Peak sputum concentrations of colistin following 
delivery by inhalation are in the range of 1–40 µg ml−1, 
declining to 1–10 µg ml−1 12 h post- dose [37, 38], well below 
the concentrations necessary to observe significant killing of 
bacteria in entrenched biofilms in our lung model. Colistin 
dose is limited by its nephrotoxicity. Our results underline 
the reasons why antibiotics cannot completely clear biofilm 
infection once it is established: the large doses required to 
penetrate and kill bacteria in large biofilm aggregates are not 
physiologically achievable.
EVPL is a tractable and reproducible model for growth of in 
vivo- like P. aeruginosa biofilms. Our experiments using EVPL 
and SCFM alongside standard antibiotic susceptibility testing 
platforms demonstrate three important microbiological 
results. First, we confirm that in- host diversity may be impor-
tant for overall infection AMR: different P. aeruginosa clones 
taken from a single CF sputum sample have different MICs 
and MBECs in vitro in Müller–Hinton broth and SCFM, and 
different MBCs in the EVPL biofilm model. Second, growth 
as in vivo- like biofilm in EVPL increases colistin tolerance 
well beyond what is observed in the Calgary device, even 
when SCFM is used in place of Müller–Hinton broth. This 
underlines the limitations of in vitro models of in vivo 
biofilms. Finally, the results confirm that the in vivo biofilm 
prevents free diffusion of colistin to bacterial cells; most 
colistin administered remains in the SCFM surrounding the 
biofilm. Clinicians currently have little information beyond 
planktonic or agar plate MIC to support their choice or dose 
of antibiotic, so if the EVPL biofilm methodology could be 
used with microbiological samples from people with biofilm 
infections (e.g. expectorated sputum), it could facilitate 
personalized diagnostic AST with greater predictive power, 
and improved antibiotic stewardship.
Various formulations of artificial CF sputum or mucus 
are available [13, 23, 39]. We chose to work with a version 
designed following chemical comparison with CF sputum 
samples and validated by comparing the transcriptome, 
preferred carbon sources and quorum- sensing signalling 
activity of a well- characterized laboratory strain of P. aerugi-
nosa in the SCFM and in CF sputum [23]. A modified version 
of SCFM, termed SCFM2, was later developed in the same 
research group. This adds bovine maxillary mucin, salmon 
sperm DNA, N- acetyl glucosamine and dioleoylphosphati-
dylcholine to the medium to further match the composition 
of CF sputum [39]. Crucially, colistin binds mucins [40], thus 
the use of SCFM without mucin allowed us to interrogate the 
role of bacterially produced components of the biofilm matrix 
in hindering access of colistin to cells. Further, we have shown 
that some key aspects of P. aeruginosa biology (total biofilm 
load, purine metabolism, production of quorum- sensing 
signal and virulence factors) do not significantly change in 
the EVPL model when SCFM2 is substituted for SCFM, and 
that extracellular DNA is present in P. aeruginosa biofilms 
grown in EVPL+SCFM [24]. Given the extra cost and time 
required to prepare SCFM2 (which requires sterilization of 
the mucin and large- scale phenol extraction of commercially 
sourced salmon sperm DNA prior to use), we propose that 
use of EVPL+SCFM represents an adequate balance between 
physiological relevance and accessibility for much research on 
P. aeruginosa. No model is a perfect match for in vivo condi-
tions, and this model provides a platform for performing 
AST in a more in vivo- like context than standard laboratory 
media, while remaining cheap and straightforward to imple-
ment. While use of SCFM2 may further enhance the likeness 
of EVPL biofilms to in vivo CF biofilms, we conclude that 
individual researchers must make this choice based on their 
exact study question and local constraints.
These results also suggest that EVPL can be combined with 
BODIPY labelling of in- use or novel antibiofilm agents to 
produce a cheap and simple method for assessing how 
well these molecules enter the biofilm matrix. Methods 
such as confocal or super- resolution microscopy, or mass 
spectrometry- based imaging, are already used to visualize 
how drugs penetrate biofilms, but these require specialized 
and expensive equipment: this much simpler methodology 
could speed up biofilm efficacy screening for new antibiotics, 
and for adjuvants proposed to enhance biofilm entry of 
antibiotics. The main limitation of this approach is unreli-
able recovery and/or quantitation of BODIPY/colistin at the 
lowest exposure dose used (2 µg ml−1). Further optimization 
of the protocol may allow the use of lower concentrations of 
labelled molecules, or alternative approaches such as HPLC or 
ELISA may need to be used when working with low concen-
trations. A second potential limitation is our assumption of 
uniform biofilm coverage of the tissue in calculating biofilm 
concentrations of BODIPY/colistin. More detailed analysis 
of light/confocal microscopy images, or quantification of 
matrix components in biofilms produced by different strains, 
would be necessary to produce more accurate calculations 
of biofilm volume and thus BODIPY/drug concentration. 
The present research focuses on CF, but the combination 
of an ex vivo model using host- mimicking surfaces/media 
plus fluorescently tagged antibiotics could also be applied to 
work on other hard- to- treat biofilm infections, e.g. ventilator- 
associated pneumonia [41], chronic obstructive pulmonary 
disease [42], chronic wounds [43] or medical device infec-
tions [44].
Understanding why biofilms are so refractory to treatment 
and finding new anti- biofilm therapies are priorities in bacte-
riological research and in industrial R and D [45]. Our results 
underline the extent and diversity of biofilm matrix resist-
ance to antibiotic entry in CF- like biofilm; they also provide 
a platform for more mechanistic exploration of the properties 
of the in vivo biofilm matrix.
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